| Name | Title | Contact Details |
|---|
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.
Bennet Office Technologies is a Willmar, MN-based company in the Business Services sector.
AIRWAY MANAGEMENT INC is a Dallas, TX-based company in the Business Services sector.
Landarch Systems Inc is a Vernon Hills, IL-based company in the Business Services sector.
Sequel Med Tech is a healthcare technology company based in Manchester, New Hampshire, dedicated to advancing drug delivery systems for diabetes management. The company focuses on creating innovative insulin delivery solutions that enhance the lives of people with diabetes. Their flagship product, the twiist™ Automated Insulin Delivery (AID) System, features advanced technology for precise insulin delivery and is designed for everyday wear. This system utilizes the Loop algorithm to automatically adjust insulin delivery, providing clinically meaningful benefits. Sequel Med Tech collaborates with healthcare providers, employers, and pharmaceutical companies to improve access to insulin therapy and develop new drug delivery solutions. They are actively working on integrating their twiist AID System with Abbott’s glucose-ketone sensor to enhance early detection of rising ketones, aiming to reduce the risk of diabetic ketoacidosis in individuals with type 1 diabetes. Through these efforts, Sequel Med Tech strives to simplify diabetes care and improve health outcomes for those who require insulin therapy.